Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations - Sorbonne Université Access content directly
Conference Papers Year : 2018
No file

Dates and versions

hal-03970061 , version 1 (02-02-2023)

Identifiers

  • HAL Id : hal-03970061 , version 1

Cite

N Hopkins P, M Krempf, E Bruckert, G Luc, S Donahue, et al.. Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations. Congress of the European-Society-of-Cardiology, Aug 2018, Munich (Allemagne), Germany. ⟨hal-03970061⟩
3 View
0 Download

Share

Gmail Mastodon Facebook X LinkedIn More